Roivant Sciences Ltd.
ROIV
$27.85
-$0.25-0.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -134.23% | 49.18% | -8.18% | -221.90% | 173.59% |
| Total Depreciation and Amortization | -24.97% | -16.12% | -86.55% | 320.17% | 1.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 174.05% | -245.61% | 729.89% | 97.32% | -566.30% |
| Change in Net Operating Assets | 32.47% | 119.04% | -207.78% | 164.94% | -615.08% |
| Cash from Operations | -5.83% | 9.16% | -18.44% | 16.74% | 22.32% |
| Capital Expenditure | 162.88% | -94.50% | -397.53% | 55.61% | -83.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -51.48% | 39.91% |
| Other Investing Activities | -18.50% | 111.86% | -208.16% | 231.74% | 108.86% |
| Cash from Investing | -9.09% | 111.09% | -201.07% | 136.57% | 113.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -2,578.18% |
| Issuance of Common Stock | 72.58% | 129.79% | 131.72% | -53.86% | 286.83% |
| Repurchase of Common Stock | -268.09% | 97.02% | 28.09% | -20.21% | -120.05% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 424.38% | 133.33% | -5.99% | 35.10% | -150.24% |
| Foreign Exchange rate Adjustments | -64.34% | 47.98% | 266.67% | 54.17% | -121.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16,774.26% | 99.90% | -304.02% | 2,762.21% | 99.26% |